Drug
Durvalumab
Durvalumab: highest development phase Phase 3, developed by AstraZeneca, Mirati Therapeutics, United Therapeutics. 10 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- AstraZeneca, Mirati Therapeutics, United Therapeutics
Trials
| Drug | Phase | Indication |
|---|---|---|
| Durvalumab NCT05771480 | Phase 3 | Biliary Tract Cancer |
| Durvalumab NCT03833154 | Phase 3 | Carcinoma, Non-Small-Cell Lung |
| Durvalumab NCT07877818 | Phase 3 | Gastric |
| Durvalumab NCT04774380 | Phase 3 | Extensive-stage Small Cell Lung Cancer |
| Durvalumab NCT06419179 | Phase 2 | Small Cell Lung Carcinoma |
| Durvalumab NCT03164772 | Phase 1/2 | Metastatic Non-small Cell Lung Cancer |
| Durvalumab (Cohort 1-3) NCT03317158 | Phase 1/2 | Urothelial Carcinoma |
| Durvalumab NCT04108481 | Phase 1 | Colorectal Cancer Metastatic |
| Durvalumab NCT05848843 | Phase 1 | Lung Cancer |
| Durvalumab NCT03773666 | Phase 1 | Muscle Invasive Bladder Cancer |
Latest
No recent events.
Follow Durvalumab on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.